VALYSTR · Stock research
Listed on SIX Swiss Exchange. What the market is pricing into Galderma Group (GALD.SW) in the Healthcare sector: implied growth, valuation scenarios, SEC-filed financials, and what has moved the stock.
Healthcare · Drug Manufacturers - Specialty & Generic · P/E 65.0 · revenue $5.9B (as of 2026-11-04)
Opening the full page… All companies · Research guides · What a reverse DCF shows